

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

June 2, 2022

Vimal Mehta, Ph.D. Chief Executive Officer BioXcel Therapeutics, Inc. 555 Long Wharf Drive New Haven, CT 06511

> Re: BioXcel Therapeutics, Inc. Registration Statement on Form S-3 Filed May 27, 2022 Filed 333-265277

Dear Dr. Mehta:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Michael Davis at 202-551-4385 or Celeste Murphy at 202-551-3257 with any questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Peter N. Handrinos